NBTX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Nanobiotix

NASDAQ | NBTX

22.34

USD

$0.00

(

0.00%

)

At Close (As of Dec 15, 2025)

$1.09B

Market Cap

-

P/E Ratio

-1.28

EPS

$30.35

52 Week High

$2.82

52 Week Low

HEALTHCARE

Sector

NBTX Chart

Recent Chart
Price Action

NBTX Technicals

Tags:

NBTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit -$12M
Total Revenue -$12M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$68M
Selling General And Administrative $20M
Research And Development $41M
Operating Expenses $57M
Investment Income Net -
Net Interest Income -$2.6M
Interest Income $2.6M
Interest Expense $8.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.6M
Income Before Tax -$68M
Income Tax Expense $101K
Interest And Debt Expense -
Net Income From Continuing Operations -$68M
Comprehensive Income Net Of Tax -
Ebit -$60M
Ebitda -$58M
Net Income -$68M

Revenue & Profitability

NBTX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (EUR)
Total Assets $67M
Total Current Assets $61M
Cash And Cash Equivalents At Carrying Value $50M
Cash And Short Term Investments $50M
Inventory -
Current Net Receivables $8.5M
Total Non Current Assets $6M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $7K
Intangible Assets Excluding Goodwill $7K
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $3.2M
Other Non Current Assets -
Total Liabilities $133M
Total Current Liabilities $59M
Current Accounts Payable $4.5M
Deferred Revenue -
Current Debt -
Short Term Debt $4.9M
Total Non Current Liabilities $74M
Capital Lease Obligations $4.2M
Long Term Debt $43M
Current Long Term Debt $3.7M
Long Term Debt Noncurrent -
Short Long Term Debt Total $51M
Other Current Liabilities $24M
Other Non Current Liabilities $28M
Total Shareholder Equity -$66M
Treasury Stock -
Retained Earnings -$68M
Common Stock $1.4M
Common Stock Shares Outstanding $47M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (EUR)
Operating Cashflow -$20M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.6M
Capital Expenditures $848K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$955K
Cashflow From Financing -$5.1M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout $0
Dividend Payout Common Stock $0
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$68M

yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit -$12M
Total Revenue -$12M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$68M
Selling General And Administrative $20M
Research And Development $41M
Operating Expenses $57M
Investment Income Net -
Net Interest Income -$2.6M
Interest Income $2.6M
Interest Expense $8.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.6M
Income Before Tax -$68M
Income Tax Expense $101K
Interest And Debt Expense -
Net Income From Continuing Operations -$68M
Comprehensive Income Net Of Tax -
Ebit -$60M
Ebitda -$58M
Net Income -$68M

NBTX News

NBTX Profile

Nanobiotix Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Nanobiotix SA is a cutting-edge clinical-stage biotechnology firm headquartered in Paris, France, focused on revolutionizing cancer treatment through its proprietary nanotechnology platform. The company is advancing a diverse pipeline of localized therapies that aim to enhance therapeutic efficacy while reducing adverse effects, targeting critical needs in oncology. Through strategic collaborations and a commitment to innovation, Nanobiotix is positioning itself at the forefront of cancer therapy, with the potential to substantially improve patient outcomes and reshape treatment standards globally.

LPTX
+368.57%
$2.05
WOK
-40.00%
$0.06
MASK
+36.34%
$0.41
OCG
-21.36%
$0.17
NVDA
+0.72%
$176.29
YGMZ
-61.42%
$0.02
TSLA
+3.56%
$475.31
ASST
-8.57%
$0.78
PAVS
-11.67%
$0.03
IRBT
-72.68%
$1.18
CGC
-4.59%
$1.66
ONDS
-12.11%
$7.69
AMCI
+168.26%
$7.27
PLUG
-4.31%
$2.22
AAL
+2.47%
$15.33
MIST
-2.69%
$2.34
AXDX
-61.36%
$0.03
YCBD
0.00%
$1.20
ASBP
+13.05%
$0.10
AVGO
-5.59%
$339.81
RIVN
+1.52%
$18.70
BMNR
-11.21%
$30.95
IVP
+13.54%
$0.05
PFE
+2.24%
$26.43
LAZR
-60.82%
$0.35
INTC
-0.79%
$37.51
BITF
-7.66%
$2.53
GRAB
-2.52%
$5.02
BYND
-4.58%
$1.04
BMNU
-22.40%
$6.44
F
-0.79%
$13.65
WBD
-0.90%
$29.71
ADAP
-15.14%
$0.05
AAPL
-1.49%
$274.11
SOFI
-5.35%
$25.82
CIFR
-13.54%
$14.74
ARTV
+90.90%
$6.30
IREN
-11.58%
$35.48
KVUE
-0.69%
$17.21
AMZN
-1.61%
$222.54
CLSK
-15.07%
$11.91
MARA
-7.11%
$10.70
PLTD
+0.30%
$6.48
ORCL
-2.65%
$184.92
APLD
-17.51%
$22.98
SOND
-23.45%
$0.12
SNAP
-0.68%
$7.26
DNN
-2.68%
$2.54
TLRY
-10.04%
$10.93
RMBL
+60.50%
$3.21
NFLX
-1.49%
$93.77
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
T
-1.09%
$24.31
WULF
-12.84%
$12.49
ACHR
-5.66%
$7.83
BTBT
-8.00%
$2.07
SRM
+53.27%
$10.30
RGTI
-8.93%
$23.53
BTG
+0.43%
$4.62
RKLB
-9.88%
$55.41
VZ
-0.22%
$40.80
PLTR
-0.17%
$183.25
BAC
+0.34%
$55.33
UBER
-3.81%
$81.86
BBD
+0.57%
$3.47
NIO
-0.79%
$4.99
RIG
-1.21%
$4.08
CRWV
-7.93%
$72.35
HPE
+0.75%
$24.05
AMC
-7.07%
$1.97
PFSA
-19.86%
$0.12
DVLT
-7.24%
$1.28
QBTS
-9.04%
$23.74
GOOGL
-0.34%
$308.22
BURU
-1.12%
$0.20
HOOD
-3.54%
$115.26
SOUN
-7.38%
$10.79
CAN
-6.13%
$0.78
AMD
-1.51%
$207.58
ATPC
-9.94%
$0.12
MU
-1.50%
$237.50
PCG
+1.31%
$15.36
MSTR
-8.14%
$162.08
RR
-14.56%
$3.52
HBAN
-0.44%
$17.74
TWOH
0.00%
$0.00
IMG
+6.17%
$1.72
AFMD
-34.94%
$0.18
MSFT
-0.77%
$474.82
URG
+3.90%
$1.33
TE
-5.42%
$5.06
VALE
+0.63%
$12.77
CMG
-0.55%
$35.94
VIVK
-15.68%
$0.06
CLYM
+27.00%
$3.81
IONQ
-8.50%
$46.07
NCLH
+3.78%
$21.65
GPUS
-5.19%
$0.24
BMY
+3.58%
$54.29
LPTX
+368.57%
$2.05
WOK
-40.00%
$0.06
MASK
+36.34%
$0.41
OCG
-21.36%
$0.17
NVDA
+0.72%
$176.29
YGMZ
-61.42%
$0.02
TSLA
+3.56%
$475.31
ASST
-8.57%
$0.78
PAVS
-11.67%
$0.03
IRBT
-72.68%
$1.18
CGC
-4.59%
$1.66
ONDS
-12.11%
$7.69
AMCI
+168.26%
$7.27
PLUG
-4.31%
$2.22
AAL
+2.47%
$15.33
MIST
-2.69%
$2.34
AXDX
-61.36%
$0.03
YCBD
0.00%
$1.20
ASBP
+13.05%
$0.10
AVGO
-5.59%
$339.81
RIVN
+1.52%
$18.70
BMNR
-11.21%
$30.95
IVP
+13.54%
$0.05
PFE
+2.24%
$26.43
LAZR
-60.82%
$0.35
INTC
-0.79%
$37.51
BITF
-7.66%
$2.53
GRAB
-2.52%
$5.02
BYND
-4.58%
$1.04
BMNU
-22.40%
$6.44
F
-0.79%
$13.65
WBD
-0.90%
$29.71
ADAP
-15.14%
$0.05
AAPL
-1.49%
$274.11
SOFI
-5.35%
$25.82
CIFR
-13.54%
$14.74
ARTV
+90.90%
$6.30
IREN
-11.58%
$35.48
KVUE
-0.69%
$17.21
AMZN
-1.61%
$222.54
CLSK
-15.07%
$11.91
MARA
-7.11%
$10.70
PLTD
+0.30%
$6.48
ORCL
-2.65%
$184.92
APLD
-17.51%
$22.98
SOND
-23.45%
$0.12
SNAP
-0.68%
$7.26
DNN
-2.68%
$2.54
TLRY
-10.04%
$10.93
RMBL
+60.50%
$3.21
NFLX
-1.49%
$93.77
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
T
-1.09%
$24.31
WULF
-12.84%
$12.49
ACHR
-5.66%
$7.83
BTBT
-8.00%
$2.07
SRM
+53.27%
$10.30
RGTI
-8.93%
$23.53
BTG
+0.43%
$4.62
RKLB
-9.88%
$55.41
VZ
-0.22%
$40.80
PLTR
-0.17%
$183.25
BAC
+0.34%
$55.33
UBER
-3.81%
$81.86
BBD
+0.57%
$3.47
NIO
-0.79%
$4.99
RIG
-1.21%
$4.08
CRWV
-7.93%
$72.35
HPE
+0.75%
$24.05
AMC
-7.07%
$1.97
PFSA
-19.86%
$0.12
DVLT
-7.24%
$1.28
QBTS
-9.04%
$23.74
GOOGL
-0.34%
$308.22
BURU
-1.12%
$0.20
HOOD
-3.54%
$115.26
SOUN
-7.38%
$10.79
CAN
-6.13%
$0.78
AMD
-1.51%
$207.58
ATPC
-9.94%
$0.12
MU
-1.50%
$237.50
PCG
+1.31%
$15.36
MSTR
-8.14%
$162.08
RR
-14.56%
$3.52
HBAN
-0.44%
$17.74
TWOH
0.00%
$0.00
IMG
+6.17%
$1.72
AFMD
-34.94%
$0.18
MSFT
-0.77%
$474.82
URG
+3.90%
$1.33
TE
-5.42%
$5.06
VALE
+0.63%
$12.77
CMG
-0.55%
$35.94
VIVK
-15.68%
$0.06
CLYM
+27.00%
$3.81
IONQ
-8.50%
$46.07
NCLH
+3.78%
$21.65
GPUS
-5.19%
$0.24
BMY
+3.58%
$54.29
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.